SEC Comment Letter for SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Dec 29, 2020
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Dec. 29, 2020 · CIK: 0001061027 · Accession: 0000000000-20-012539
AI Filing Summary & Sentiment
File numbers found in text: 333-251567
Letter
United States securities and exchange commission logo December 29, 2020 Dayton Misfeldt Interim Chief Executive Officer SUNESIS PHARMACEUTICALS INC 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Re:SUNESIS PHARMACEUTICALS INC Registration Statement on Form S-4 Filed December 22, 2020 File No. 333-251567 Dear Mr. Misfeldt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John McKenna
Show Raw Text
United States securities and exchange commission logo
December 29, 2020
Dayton Misfeldt
Interim Chief Executive Officer
SUNESIS PHARMACEUTICALS INC
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
Re:SUNESIS PHARMACEUTICALS INC
Registration Statement on Form S-4
Filed December 22, 2020
File No. 333-251567
Dear Mr. Misfeldt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John McKenna